Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31739266 | 1.00 | FOLH1 (0.50) | FOLH1GGT1CPB2SLC6A5GSR | |
| Ammonia Solution, Strong SCHEMBL4951217 | 0.98 | FOLH1 (0.49) | FOLH1GGT1CPB2SLC6A5GSR | |
| Hydrochloric Acid SCHEMBL20482193 | 0.98 | FOLH1 (0.49) | FOLH1GGT1CPB2SLC6A5GSR | |
| SCHEMBL2151316 | 0.94 | FOLH1 (0.57) | FOLH1GGT1CPB2SLC6A5GSR | |
| SCHEMBL2151319 | 0.94 | FOLH1 (0.57) | FOLH1GGT1CPB2SLC6A5GSR | |
| Ammonia Solution, Strong SCHEMBL4951257 | 0.92 | FOLH1 (0.56) | FOLH1GGT1CPB2SLC6A5GSR | |
| Hydrochloric Acid SCHEMBL28514579 | 0.92 | FOLH1 (0.56) | FOLH1GGT1CPB2SLC6A5GSR | |
| Hydrochloric Acid SCHEMBL29268898 | 0.92 | FOLH1 (0.56) | FOLH1GGT1CPB2SLC6A5GSR | |
| Water SCHEMBL28303756 | 0.92 | FOLH1 (0.56) | FOLH1GGT1CPB2SLC6A5GSR | |
| Hydrochloric Acid SCHEMBL3647090 | 0.92 | FOLH1 (0.56) | FOLH1GGT1CPB2SLC6A5GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115656161-A | Phthalic dicarboxaldehyde disinfectant concentration detection indicator card and preparation method thereof | 利康医药科技江苏有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-1151781-C | Use of nitric oxide donors or nitric oxide inhibitors for regulation cervical dilatation and extensiblity | ���ֹɷݹ�˾ | 2004-06-02 | — | — | CN | claimed |
| CN-1182366-A | Use of nitric oxide donors or nitric oxide inhibitors to modulate cervical dilation and dilation | UNIV TEXAS (US) | 1998-05-20 | — | — | CN | claimed |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4341262-A1 | AXL INHIBITOR COMPOUNDS | Arcus Biosciences, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240010751-A1 | MULTISPECIFIC BINDING AGENTS AND USES THEREOF | EXELIXIS, INC. (US) | 2024-01-11 | — | — | US | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023220626-A2 | 5T4 BINDING AGENTS AND USES THEREOF | EXELIXIS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357391-A1 | CD47 BINDING AGENTS AND USES THEREOF | EXELIXIS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023154730-A2 | MULTISPECIFIC BINDING AGENTS AND USES THEREOF | EXELIXIS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-2996706-B1 | APOLIPOPROTEIN MIMETICS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2019136118-A2 | CELL-ASSOCIATING IMMUNOLOGIC ADJUVANTS FOR TREATMENT ENHANCEMENT | ACADEMIA SINICA (TW) | 2019-07-11 | — | — | WO | disclosed |
| EP-3355935-A1 | PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| CN-101237885-A | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO (JP) | 2008-08-06 | — | — | CN | disclosed |
| CN-1129606-C | Heptapeptide oxytocin analofues | FERRING BV (NL) | 2003-12-03 | — | — | CN | disclosed |
| CN-1418110-A | Remedies for sjoegrens syndrome | ONO PHARMACEUTICAL CO (JP) | 2003-05-14 | — | — | CN | disclosed |
| CN-1096855-C | Composition for treating and inducing nitric oxide synthase expression and application thereof | MEDINOX INC (US) | 2002-12-25 | — | — | CN | disclosed |
| CN-1238781-A | Heptapeptide oxytocin analofues | FERRING BV (NL) | 1999-12-15 | — | — | CN | disclosed |
| CN-1202824-A | Combinational therapeutic methods employing nitric oxide scavengers | MEDINOX INC (US) | 1998-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | FOLH1 450/4885GGT1 186/4885CPB2 3040/4885 |
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | FOLH1 3444/4885GGT1 1619/4885CPB2 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.